9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Estimated reading time: < 1 min

Condition: Cancer

Estimated Enrollment: 20

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Incidence of treatment-emergent adverse events (TEAEs),  Incidence of treatment-emergent serious adverse events (TESAEs),  Incidence of drug-related TEAEs, Incidence of drug-related TESAEs

Interventions: BAY94-9343 (Anetumab ravtansine),

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: October 31, 2024

Completion Date: October 31, 2024

Last  Posted Date: August 7, 2019

Location: Univ.of California-San Diego Moores Cancer Center, La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03926143

Was this article helpful?
Dislike 0